Novartis ships influenza vaccine to US
The company intends to send around 30 million doses of its US Food and Drug Administration (FDA) approved seasonal influenza vaccine for the US market. Novartis‘ Fluvirin influenza
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.